IBA announces its partnership with Beckman Coulter for the distribution of IBA's Streptamer product portfolio
“We are very pleased that we have found Beckman Coulter as an ideal partner with a strong global reputation in cell sciences for selling our Streptamer products to customers in North America,” said Lothar Germeroth, CEO of IBA GmbH. “We believe that the expansion to the North American market through the experienced sales and marketing team of Beckman Coulter will strongly enhance the visibility of our Streptamer technology as a platform for unique immunological research applications.”
Streptamer technology allows for antigen-specific staining and isolation of naturally occurring T-cells with reversible reagents that do not impact cell expression, trigger activation or induce functional changes. Since all reagents used for staining or isolation can be removed with biotin, the isolated T-cells remain uncompromised and retain phenotypic and functional characteristics undistinguishable from naturally occurring cells.
“The addition of the Streptamer technology to Beckman Coulter´s tetramer product lines will open up new possibilities for researchers to study cells in their natural state and under native conditions,“ said Brad Calvin, vice president of Beckman Coulter´s Flow Cytometry Business Center. “This makes the Streptamer technology a valuable tool for immunological research and could facilitate the discovery of novel therapeutic approaches.”
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.